Get to Know Dr. Keisuke Shirai
Thoracic oncologist Dr. Keisuke Shirai is an associate professor of medicine at the Geisel School of Medicine at Dartmouth in Hanover, New Hampshire. He is focused on his clinical patients and advancing the treatment of cancer for all.
His current clinical trial research revolves around targeted immunotherapy drugs such as pembrolizumab, nivolumab and ipilimumab, along with the UV1 cancer vaccine. Many of the drugs in his trials are also being studied with mesothelioma, a rare cancer with no definitive cure.
Shirai is a key member of the acclaimed Comprehensive Thoracic Oncology Program at Dartmouth-Hitchcock Norris Cotton Cancer Center, which is known for its personalized and multidisciplinary approach to treatment. He works closely with specialists such as radiation oncologists, pathologists and thoracic surgeons to formulate a unique plan for each of his patients.
He joined the cancer center in 2015 after completing his fellowship at the Medical University of South Carolina.
His clinical focus today is on lung cancer, pleural mesothelioma, melanoma and palliative care.
Specialties of Dr. Keisuke Shirai
- Lung cancer
- Pleural mesothelioma
- Palliative care
- Esophageal cancer
Dr. Keisuke Shirai’s Experience and Medical Education
- Dartmouth-Hitchcock Norris Cotton Cancer Center
- Medical University of South Carolina (Fellowship)
- United States Naval Hospital (Internship)
- University of Pittsburgh Medical Center (Residency)
- Hokkaido Cancer Center, National Sapporo Hospital, Hokkaido, Japan (Residency)
- Aso Iizuka Hospital, Fukuoka, Japan (Residency)
Awards and Certifications
- Medical Oncology Board Certification
- Hospice and Palliative Medicine Board Certification
- Internal Medicine Board Certification
- Castle Connolly Top Doctor Award (2019, 2020 and 2021)
- Healthgrades Honor Roll
Publications of Dr. Keisuke Shirai
- Cao, Y., Afzal, M.Z. & Shirai, K. (2021, August). Does denosumab offer survival benefits? Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitors. Journal of Thoracic Disease.
- Bernhardt, E.B. et al. (2020, June 12). Molecular matching and treatment strategies for advanced stage lung cancer at Dartmouth-Hitchcock Medical Center: A three-year review of a Molecular Tumor Board. Practical Laboratory Medicine.
- Zhang, T. et al. (2020, June 10). Proliferation potential and response to nivolumab in clear cell renal cell carcinoma patients. OncoImmunology.
- Afzal, M.Z. et al. (2019, March 1). An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer. Annals of Translational Medicine.
Thank you for your feedback. Would you like to speak with a Patient Advocate?